Nearly 33% of patients in eye care clinics present with complaints about dry eye signs and symptoms. Clinicians remain challenged with both the diagnosis and best treatment options for dry eye disease (DED) because, to date, multiple causes of the disorder have been identified. This activity will help to inform clinicians on methods to improve the care of patients with DED.
This activity is supported by an unrestricted educational grant from Sun Pharmaceutical Industries.
At the completion of this educational activity, you will be better able to:
Provided by Evolve Medical Education
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring. material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Sponsored by:
Evolve is an approved COPE Administrator. This course is COPE approved for 1.0 hour of CE credit for optometrists.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Jennifer Loh, MD
Founder
Loh Ophthalmology Associates
Miami, FL
Vance Thompson, MD, FACS
Founder, Vance Thompson Vision
Professor of Ophthalmology
University of South Dakota
Sanford School of Medicine
Sioux Falls, SD
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Jennifer Loh, MD, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Sight Sciences, Allergan, Novartis, Kala Pharmaceuticals, Johnson & Johnson Vision, and Eyevance. Grant/Research Support: Sight Sciences. Speakers Bureau: Aerie Pharmaceuticals, Kala Pharmaceuticals, Sun Pharmaceutical Industries, Sight Sciences. Shareholder: Novabay
Vance Thompson, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Acufocus, Alcon Vision, Allergan, Allotex, Avellino, Avisi Technologies, Bausch + Lomb, BRIM Biotechology, Carl Zeiss Meditec, Centricity, Conjtac, CSO, D&D Biopharmaceuticals, Equinox, Euclid Systems, Expert Opinion, eyeBrain Medical, Eyedetec, EyeGate Pharma, Eyesafe, FemtoVision, Foresight Robotics, Glaukos, Imprimis, iVeena, Johnson & Johnson Vision, Leica, Melt Pharmaceuticals, Ocular Innovations, OneFocus, ORA, Oyster Point Pharma, Percept, ReFocus, RxSight, Sight Sciences, Stuart Therapeutics, Tarsus Rx, TearClear, TearOptix, TherOptix, Treehouse Health, Veracity, Visant, Visus, and Vivior. Grant/Research Support: Acufocus, Alcon Vision, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Centricity, Equinox, EyeGate Pharma, Glaukos, Johnson & Johnson Vision, Sight Sciences. Speakers Bureau: Acufocus, Alcon Vision, Glaukos, Johnson & Johnson Vision. Shareholder: Acufocus, Al Optics, Allotex, Avellino, Avisi Technologies, Centricity, Conjtac, D&D Biopharmaceuticals, Equinox, Euclid Systems, Expert Opinion, eyeBrain Medical, Eyedetec, EyeGate Pharma, Eyesafe, FemtoVision, Foresight Robotics, iVeena, Melt Pharmaceuticals, Ocular Innovations, OneFocus, Oyster Point Pharma, Percept, RxSight, Sight Sciences, Stuart Therapeutics, Tarsus Rx, TearClear, TearOptix, TherOptix, Treehouse Health, Veracity, Visant, and Vivior
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Sun Pharmaceutical Industries, or Sight Sciences
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Eric D. Donnenfeld, MD
Marjan Farid, MD
Jason J. Jones, MD
Eva I. Liang, MD, FACS
Carlton Yuen, MD
